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Summary 
 
Gene targeting by homologous recombination at chromosomal endogenous loci 
has traditionally been considered a low-efficiency process. However, the 
effectiveness of such so-called genome surgery has recently been drastically 
improved through technical developments, chiefly the use of designer nucleases 
like zinc-finger nucleases (ZFNs), meganucleases and transcription activator-like 
effector nucleases (TALENs). These enzymes are custom-designed to recognize 
long target sites and introduce double-strand breaks (DSBs) at specific target 
loci in the genome, which in turn mediate significant improvements in the 
frequency of homologous recombination. Here, we describe a Southern blot-
based assay that allows detection of gene repair and estimation of repair 
frequencies in a cell population, useful in cases where the targeted modification 
itself cannot be detected by restriction digest. This is achieved through detection 
of a silent restriction site introduced alongside the desired mutation, in our 
particular example using integration-deficient lentiviral vectors (IDLVs) coding 
for ZFNs and a suitable targeting template matrix. 
Key words: Zinc-finger nucleases, integration-deficient lentiviral vectors, 
homologous recombination, Southern blot. 
 
1. Introduction 
 
Gene targeting is a process in which information from a DNA molecule 
introduced into a cell replaces that in the corresponding chromosomal segment. 
The process relies on homologous recombination, one of the major cellular 
pathways for DSB repair. Gene targeting is a very low efficiency process that can 
be considerably enhanced by the introduction of a DSB at the target locus. This 
major development was initially achieved using the S. cerevisiae homing 
endonuclease I-SceI and pre-engineered target sites (reviewed in [1]). Practical 
application had to wait for the development of target site-specific chimeric 
nucleases, initially ZFNs and I-CreI-based meganucleases, and more recently 
TALENs. These enzymes can introduce DSBs at specific target sites, which in turn 
stimulate the cell's endogenous homologous recombination machinery [2, 3]. 
The first example of targeted genome manipulation in vitro with engineered 
nucleases at a human endogenous locus was based on the use of ZFNs [4]. These 
enzymes have also mediated the first example of in vivo genome surgery [5]. The 
following references provide recent reviews of engineered nuclease technology 
[6-8]. 
 
An important requirement to assess the efficiency of gene targeting is the 
availability of an in vitro assay to detect the phenomenon and estimate its 
frequency. While deep-sequencing technologies have facilitated this 
considerably, normally through custom services, it is still useful to have a gel-
based assay for in-house estimation of gene targeting frequencies. Here, we 
describe in detail a Southern blot-based protocol that allows detection and 
quantification of a surrogate restriction site, to estimate correction of a linked 
targeted point mutation in cell lines and primary cells. 
 
The protocol we will describe here does not require a particular type of 
designer nuclease, but was developed using a ZFN, and for this reason a brief 
description of this particular type of enzymes follows. ZFNs are heterodimeric 
enzymes that combine the non-specific cleavage domain from FokI restriction 
endonuclease with DNA-binding zinc-finger domains. The monomers are 
composed of several tandemly arranged zinc-finger domains (each recognizing a 
tri-nucleotide in the target site) and a nuclease domain. The enzyme dimerizes 
through the FokI domains, providing a tool to recognize a specific site in which a 
spacer of about six nucleotides where the cutting will occur is flanked by the 
sites recognized by the two monomers (Figure 1). Because the recognition 
specificities of the zinc-finger domains can be easily manipulated experimentally, 
ZFNs offer a general way to induce targeted site-specific DSBs in the genome [9]. 
A major issue with designer nucleases is off-target cutting-mediated mutagenesis 
or toxicity, whereby unintended DSBs introduced in the target genome lead to 
unwanted effects [10]. The development of obligate heterodimeric ZFNs and 
further refinements of the nuclease domain have helped to address this problem 
[11-15], but generic concerns with nuclease off-target cutting remain. In any 
case, targeted nuclease technology has become a powerful tool for genetic 
manipulations, not only for site-specific genome surgery in plant and 
mammalian genomes, but potentially also for human therapy. 
 
Firstly, once a strategy for targeted modification has been decided upon, a 
target site for the nuclease must be chosen. As gene conversion tracts are 
generally short [16, 17], the nuclease recognition site should be chosen as close 
as possible to the target site to be modified. The ZiFiT software package 
identifies potential target sites in DNA sequences for which ZFNs maybe 
engineered [18]. Once the ZFN is obtained, its cutting efficiency can be tested 
using the surveyor CelI assay as described by Guschin et al. [19] or deep 
sequencing, in both cases detecting modifications introduced at the target site by 
non-homologous end-joining repair of the induced DSBs. 
 
Secondly, a targeting construct (repair matrix) must be obtained. Our goal was 
the correction of a point mutation in a mouse gene. To avoid the presence of 
heterologies that can reduce the frequency of gene targeting [20], we prepared a 
1.7 kb corrective template using high-fidelity PCR amplification of genomic DNA 
from wild-type fibroblasts of the same mouse strain, followed by DNA 
sequencing to check for absence of unwanted sequenced changes. Afterwards, 
using standard site-directed mutagenesis, we introduced a silent diagnostic 
restriction site on the template, as close as possible to the site that would correct 
the genomic mutation (Figure 2). As our ZFN target site was located 3’ to the 
mutation on the target gene, we placed our silent site 5’ to the wild-type site on 
the correcting template. In this configuration, incorporation of the silent 
restriction site on the targeted gene would ensure the presence of the linked 
wild-type nucleotide and hence the reversion of the mutation (Figure 2). 
 
Delivery of the corrective cassette and the genes encoding the ZFN monomers 
may be achieved by several methods, in our case integration-deficient lentiviral 
vectors (IDLVs) [21, 22]. Once the target cells have been transfected or 
transduced with the relevant vectors, the cellular DNA is extracted to analyze for 
the presence of the desired change. For this the DNA sequence around the target 
site is PCR-amplified with primers external to the corrective template, to prevent 
amplification of template molecules not yet diluted out or randomly integrated 
in the cells (Figure 3A). The PCR product is then digested overnight with the 
diagnostic restriction enzyme. The digestion mixture is loaded onto an agarose 
gel, electrophoresed, transferred onto a membrane and subsequently hybridized, 
using the initial PCR product as a labeled probe (Figure 3B). In this manner, we 
have been able to visualize the three bands expected if homologous 
recombination-mediated gene repair occurs between the cellular DNA and the 
donor DNA template. Using Image J, it was also possible to quantify by 
densitometry the 1.7 kb band from untargeted alleles and the 1 kb band 
diagnostic for gene repair, and to estimate the percentage of gene targeting from 
their relative values. We chose not to include the diagnostic 0.7 kb band on the 
densitometry measurements because of the overlap with non-specific smear at 
low molecular weight (Figure 3C). This method has allowed us to estimate 
frequencies of correction of about 2% of alleles in the population. 
 
 
2. Materials 
 
2.1: In vitro transduction of fibroblasts with IDLVs coding for the ZFN monomers 
and the repair template 
 
1. Mouse fibroblasts. 
2. Culture medium:Dulbecco’s Modified Eagle Medium (DMEM with high 
glucose, Gibco/Invitrogen) supplemented with 10% fetal bovine serum 
(FBS, Gibco/Invitrogen) and 1X penicillin/streptomycin (100X 
solution, Gibco/Invitrogen). 
3. Trypsin solution (0.25% trypsin/EDTA, Gibco/Invitrogen). 
4. IDLVs encoding ZFN1, ZFN2 and template. A complete protocol for 
producing and titrating lentiviral particles has been described by Giry-
Laterrière et al.[23]. Suggestions pertaining to IDLVs have been 
published before [22]. 
 
2.2: Genomic DNA extraction and PCR amplification of the targeted region 
 
1. DNeasy Blood & Tissue Kit (Qiagen). 
2. 100% EtOH. 
3. PCR reaction: 10X LongAmpTaq reaction buffer (NEB), 10 mM dNTPs, 
external primers to the template diluted to10 μM, LongAmpTaq 
polymerase (NEB), dH2O. 
4. 0.7% agarose gel in 1X TAE. 50X TAE: In 900ml dH2O 242g Tris base, 
57.1ml Glacial Acetic Acid, 18.6 g EDTA. Adjust pH to 8 and the volume 
to 1L. 
5. Appropriate waste disposal for ethidium bromide-contaminated 
materials following local H&S guidelines. 
 
2.3: Restriction enzyme digestion of PCR product, agarose gel electrophoresis 
and salt transfer 
1. Appropriate restriction enzyme (NEB), 10X NEB buffer, 10X BSA if 
required according to manufacturer’s instructions. 
2. DNA size markers without loading dye. 
3. 10X Nick Translation buffer (NTB): 0.5M TrisHCl pH 7.5, 0.1 M MgSO4, 
1 mM DTT, 500 μg/ml BSA 
4. CTG: 0.5 mMof each dCTP, dTTP and dGTP in 10 mM TrisHCl pH 7.5. 
5. [α-32P]dATP. 
6. DNA Polymerase I, Large (Klenow) Fragment (NEB, M0210S). 
7. TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0). 
8. Pharmacia Microspin S-300HR columns. 
9. 0.7% agarose gel in 1X TAE, cast in large electrophoresis tray (~200 
ml) in order to obtain a good separation of the digested fragments.  
10. 0.25 N HCl: 975 ml ddH2O with 25ml of 37% HCl added drop-wise 
(make up in a fume hood). 
11. Denaturing solution: 0.4 N NaOH (16 g), 0.6 M NaCl (35.08 g), ddH2O to 
1 l. 
12. Neutralizing solution: 1.5 M NaCl (87.66 g), 0.5 M TrisHCl (60.55 g), 32 
ml HCl, ddH2O to 1 l. 
13. GeneScreen Plus membrane. 
14. 20XSSC: 3M NaCl (175.35 g), 0.3 M tri-sodium citrate dehydrate (88.23 
g), ddH2O to 1 l. 
15. Whatmann 3MM paper. 
16. Blotting paper. 
17. Glass plate (same size as agarose gel). 
18. Bottle weighting about 500 g. 
19. 0.4 N NaOH: 16 g NaOH, ddH2O to 1 l. 
20. 0.2 M TrisHCl pH 7.5 or 8, 1XSSC: 40 ml 1M Tris, 10 ml 20XSSC, 150 ml 
ddH2O. 
21. Appropriate waste disposal for radioactively contaminated materials, 
according to local H&S guidelines. 
 
2.4: Probe labeling and hybridization 
1. TE buffer. 
2. 60 ng/μl dN6 (random hexanucleotides) (Sigma, H-0268). 
3. 10X random priming buffer (RP): 0.5 M TrisHCl pH 6.9, 0.1 M MgSO4, 1 
mM DTT (store at -20°C). 
4. CTG: 0.5mM of each dCTP, dTTP and dGTP in 10 mM TrisHCl pH 7.5. 
5. [α-32P]dATP 
6. DNA Polymerase I, Large (Klenow) Fragment (NEB, M0210S). 
7. Pharmacia Microspin S-300HR columns. 
8. Church mix (1% BSA, 7% SDS, 0.5 M Phosphate buffer): prepare 
solutions 1,2 and 3, mix them and make up to 500 ml with ddH2O. 
9. Solution 1 for Church mix: 35 g SDS dissolved in ddH2O and made up to 
300 ml. 
10. Solution 2 for Church mix: 5 g BSA dissolved in ddH2O and made up to 
50 ml. 
11. Solution 3 for Church mix: 28.4 g Na2HPO4, 6.9 g NaH2PO4.H2O 
dissolved in water (warming up in microwave oven) and made up to 
125 ml. 
12. 2XSSC 0.5% SDS: 100 ml 20XSSC, 5 g SDS, ddH2O to 1 l. 
13. Plastic bag suitable for heat sealing. 
 
3. Methods 
 
3.1: In vitro transduction of fibroblasts with IDLVs coding for ZFN monomers and 
the repair template 
 
 Carry out all procedures under sterile cell culture conditions. 
 
1. Wash a 75-cm2 flask of fibroblasts (70-80% confluent) with 15 ml PBS, 
and trypsinize the cells using 1.5 ml trypsin-0.25% EDTA. 
2. Resuspend the cells in 10 ml of DMEM 10% FBS and transfer them to a 
15 ml conical tube. 
3. Centrifuge the cells at 478 g for 5 min, remove the supernatant and 
resuspend the pellet in 10 ml of DMEM 10% FBS. 
4. Determine the number of cells/ml using a haemocytometer. 
5. Plate out 105 cells per well in a 6-well plate. Place the plate in an 
incubator at 37°C, 5% CO2 overnight (Note 1). 
6. The next day, replace the medium with a minimum volume of fresh 
medium, ensuring that there is enough to cover the cell monolayer 
(e.g.: 0.5 ml/well for a 6-well plate). This will maximize the chances of 
interaction between vectors and cells (Note 2). 
7. Transduce with appropriate MOI (Multiplicity of infection) of ZFN1, 
ZFN2 and template vectors, using a relative ratio of 1:1:2, respectively 
(Note 3). 
8. Return the plate to the incubator for 3-4 h, then top-up each well with 
1.5 ml of fresh medium. Incubate the plate for 5 more days. 
 
3.2: Genomic DNA extraction and PCR amplification of the targeted region 
 
1. Remove media from each well, wash with 2 ml PBS and trypsinize the 
cells using 100 μl trypsin-0.25% EDTA. 
2. Resuspend the cells in 1 ml DMEM 10% FBS and then transfer to 1.5 ml 
eppendorf tubes. 
3. Centrifuge the cells at 478 g for 5 min, remove supernatant and 
resuspend pellet in 1 ml PBS. 
4. Centrifuge the cells again at 478 g for 5 min, remove supernatant and 
resuspend cells in 200 μl PBS. 
5. Proceed to genomic DNA extraction according to DNeasy Blood & 
Tissue Kit (Qiagen): 
6. Add 20 μl proteinase K and 200 μl Buffer AL and mix thoroughly by 
vortexing. 
7. Incubate the samples at 56°C for 10 min. 
8. Add 200 μl ethanol (96–100%) and mix thoroughly by vortexing. 
9. Transfer the mixture onto a DNeasy Mini spin column placed in a 2 ml 
collection tube. 
10. Centrifuge at 4,720 g for 1 min. Discard the flow-through and collection 
tube. 
11. Place the spin column in a new 2 ml collection tube. 
12. Add 500 μl Buffer AW1. 
13. Centrifuge for 1 min at 4,720 g.  
14. Discard the flow-through and collection tube. 
15. Place the spin column in a new 2 ml collection tube. 
16. Add 500 μl Buffer AW2. 
17. Centrifuge for 3 min at 14,460 g. Discard the flow-through and 
collection tube. 
18. Transfer the spin column to a new 1.5 ml or 2 ml microcentrifuge tube. 
19. Elute the DNA by adding 200 μl Buffer AE to the center of the spin 
column membrane. Incubate for 1 min at room temperature (15–25°C). 
Centrifuge for 1 min at 4,720 g and keep DNA-containing eluate.  
20. Measure DNA concentration by optical density at 260 nm (Nanodrop or 
similar). 
21. Perform a PCR amplification using primers external to the template 
DNA region: 
22. Prepare the PCR mix as follow: 
- 100 ng of genomic DNA  
- 1X LongAmpTaq reaction buffer 
- 300 μM dNTPs 
- 0.4 μM forward primer 
- 0.4 μM reverse primer 
- 2.5 U LongAmpTaq DNA polymerase (NEB, M0323S) 
- Complete to 25 μl with nuclease-free water 
23. Gently mix the reaction on ice and transfer tubes to PCR machine with 
the block preheated to 94°C. 
24. Begin thermocycling (94°C 30 sec, 30X (94°C 30 sec, 59°C 60 sec, 65°C 
1 min 20sec), 65°C 10 min, hold 4°C). 
25. Load 5 μl of the reaction in a 0.7% TAE-agarose gel containing 0.5 
μg/ml ethidium bromide and run for 50 min at 50 V. 
26. Expose the gel to UV light to verify specificity of amplification and size 
of the amplified product. 
 
3.3: Restriction enzyme digestion of PCR product, agarose gel electrophoresis 
and salt transfer 
 
 Reminder: a diagnostic restriction site will have been introduced next to 
the corrected site if homologous recombination-mediated gene repair has 
taken place. Take standard precautions when handling radioactive 
materials and dispose of waste according to local regulations. 
1. Measure the DNA concentration of each PCR product by optical density 
at 260 nm. 
2. Transfer 500 ng into clean 1.5 ml eppendorf tubes. 
3. Add: 
- 5 μl 10X enzyme buffer 
- 5 μl 10X BSA (if required) 
- 1 μl of the appropriate enzyme 
- Top-up to 50 μl with sterile distilled water. 
4. Incubate at 37°C for 16 hours. 
5. Prepare radioactive size markers (“hot ladder”) as follows (Note 4): 
6. Make up mix of: 
- 1 μg suitable DNA size marker (without loading dye) 
- 2 μl 10X nick-translation buffer (NTB) 
- 4 μl CTG 
- 1 μl (10 μCi) [α-32P]dATP 
- 1 μl Klenow (5U/μl) 
- Top up with water to 20 μl. 
7. Mix gently and incubate at room temperature for 90 min. 
8. Add 40 μl of TE buffer and mix. 
9. Count 1 μl in Biomax Cerenkov Geiger counter. 
10. Pack Pharmacia Microspin S-300HR column by spinning at 660 g for 1 
min. 
11. Load sample onto column, spin at 660 g for 2 min, keep eluate. 
12. Count 1 μl of eluate in Biomax Cerenkov Geiger counter (incorporation 
should be around 50%). 
13. Keep the hot ladder (eluate) frozen for up to several weeks if 
necessary. 
14. Cast a 200 ml 0.7% agarose gel in 1XTAE containing 0.5 μg/ml 
ethidium bromide. 
15. Load lanes with 15-45 Cerenkov Geiger counts of hot ladder or the 
totality of the digested products.  
16. Run gel overnight at 35 V in 1XTAE-buffer with 0.5 μg/ml ethidium 
bromide, in cold room. 
17. Take and save a picture. 
18. Shake the gel in 0.25 N HCl for 10min. 
19. Wash gel twice with dH2O. 
20. Shake the gel in denaturing solution for 30 min. 
21. Wash gel twice with ddH2O. 
22. Shake the gel in neutralizing solution for at least 30 min. 
23. Cut GeneScreen Plus membrane about 1cm longer and wider than the 
gel (gel stretches when smoothed on transfer platform). Cut a corner as 
an orientation reference. 
24. Pre-wet the membrane in water for a few seconds and equilibrate it in 
10XSSC for 15 min. 
25. Set-up a capillary transfer blot using 10XSSC (remove air bubbles by 
rolling pipette). Order from bottom: 
- Inverted gel (isolate the gel edges with plastic film) 
- GeneScreen Plus membrane 
- Two 10XSSC-soaked Whatman 3MM paper pieces (same size as 
gel) 
- Stack of blotting paper about 10 cm high (same size as gel) 
- Glass plate 
- Bottle weighting about 500 g 
26. Transfer overnight. 
27. Dismount the transfer blot. 
28. Shake the membrane in 0.4 N NaOH for 1 min. 
29. Shake the membrane in 0.2 M Tris-HCl pH 7.5 or 8 for 1 min. 
30. Wash membrane quickly in 2XSCC. 
31. Place the membrane DNA side up on 2XSCC-soaked Wathman 3MM 
paper. 
32. Fix in Stratagene UV cross-linker using auto cross-link function (the 
membrane can be dried on filter paper for storage or kept in 2XSSC if 
proceeding to hybridization). 
 
3.4: Probe labeling and hybridization 
 
 Reminder: to identify the bands of interest we probe the membrane with 
the starting PCR product. This fragment will hybridize with the 1.7 kb PCR 
product as well as with the 1 and 0.7 kb digested fragments (Note 5). 
Take standard precautions when handling radioactive materials and 
dispose of waste according to local regulations. 
 
1. Transfer 50-100 ng of the PCR product into a 1.5 ml eppendorf tube 
(ideally screw-cap) and top-up to 4 μl with TE buffer. 
2. Add 1 μl of 60 ng/μl dN6 and boil for 5 min in a heat-block. 
3. Transfer onto ice for 2 min and afterwards spin down for a few 
seconds at full speed. 
4. Add 12 μl of the following mixture: 
- 12 μl water 
- 3 μl 10X random priming buffer (RP) 
- 3 μl CTG. 
5. Add 2 μl (20 μCi) [α-32P]dATP (Note 6). 
6. Add 1 μl of Klenow (5U/μl). 
7. Incubate at room temperature for 1 h. 
8. Add 40 μl TE buffer. 
9. Count 1μl in Biomax Cerenkov Geiger counter. 
10. Pack Pharmacia Microspin S-300HR column by spinning at 660 g for 1 
min. 
11. Load sample onto column and spin at 660 g for 2 min, keep eluate. 
12. Count 1 μl of eluate in Biomax Cerenkov Geiger counter (incorporation 
should be around 50%). 
13. Wet the DNA membrane from step 3.3-32 in 2XSSC if it was stored dry 
and spread it in a hybridization tube. Drain 2XSSC from tube. 
14. Add 15 ml of Church mix. 
15. Pre-hybridize rotating for at least one hour at 68°C. 
16. Boil the labeled probe for 5 min in a heat-block and transfer it to ice for 
2 min. 
17. Add the boiled probe to the hybridization tube. 
18. Hybridize at 68°C rotating overnight. 
19. Discard the hybridization solution. 
20. Perform 3 quick washes and 3x10min washes with 2XSSC, 0.5% SDS at 
65°C (Note 7). 
21. Seal the membrane in a plastic bag. 
22. Expose to a Phosphoimager screen. 
23. Acquire image by using a laser scanner (Figure 3). 
 
3.5: Estimation of the percentage of corrected alleles using Image J 
 
Image J software can be freely downloaded from: 
http://rsbweb.nih.gov/ij/download.html 
1. Using Image J, quantify the intensity (I) of the relevant bands (1.7 kb, 1 
kb and 0.7 kb) on the Phosphoimager image (Note 8). 
2. The percentage of corrected alleles = (100 x (I1kb + I0.7kb)) / (I1.7kb + I1kb 
+ I0.7kb). Or if 0.7 kb band is not scanned for densitometry (Note 5), 
percentage of corrected alleles = (100 x (1.7xI1kb)) / (I1.7kb + 1.7xI1kb). 
 
4. Notes 
 
1. It is also possible to plate the cells out on the day of transduction, 
waiting for them to attach before vector is added. 
2. Another way to maximise transduction is to add vectors to the cells in 
suspension, before plating out. Briefly, put the same number of cells in 
1.5 ml eppendorf tubes in a minimum volume, add the vectors, mix 
gently and incubate at 37°C for 1 to 2 h (mix every 15 min as the cells 
will drop to the bottom of the tube). Then, either wash the cells once, 
centrifuge and resuspend them in an appropriate volume of medium 
for plating in a 6-well plate well or add medium to the eppendorf tube 
and plate out the mixture directly if a longer transduction time is 
preferred. 
3. MOI refers to the number of vector particles added per cell. As a rule of 
thumb, we would normally start with MOI 100 for the ZFN monomer 
vectors and 200 for the repair matrix. Try different ratios, keeping 1:1 
for the ZFN monomers but increasing the amount of DNA donor 
template, it may improve the rate of correction. 
4. The use of non-radioactive size markers may be possible, as the bands 
corresponding to the different sizes some times show-up with varying 
intensity due to non-specific hybridization with the radiolabeled probe. 
5. In the example shown we chose not to include the diagnostic 0.7 kb 
band on the densitometry measurements because of the overlap with 
non-specific smear at low molecular weight (Figure 3C). 
6. We use radiolabeled dATP because it is the most frequent nucleotide in 
our DNA template. You should identify the most suitable nucleotide in 
your own template. 
7. If the signal is too strong and a higher stringency wash is needed, 
proceed step-wise with 1-3x10 min washes at 65°C in:  
- 0.5XSSC, 0.5% SDS 
- 0.2XSSC, 0.5% SDS 
- 0.1XSSC, 0.5% SDS 
8. There are other program packages that allow densitometric 
quantifications, including Adobe Photoshop and Odyssey. 
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Figure Legends 
Figure 1. Schematic of ZFN bound to target DNA. A standard ZFN is a 
heterodimeric enzyme. Each monomer is made up of several zinc-fingers linked 
to a non-specific nuclease domain from FokI endonuclease. Dimerization through 
the nuclease domains allows recognition of two hemi-sites of about 12 
nucleotides each, separated by a spacer of about 6 base-pairs where cutting will 
occur. 
 
Figure 2. Gene targeting strategy. A ZFN target site has been selected 3’ to the 
point mutation to be corrected in the chromosomal locus. As this particular 
correction event cannot be detected by restriction analysis, a diagnostic 
restriction site made up of silent mutations has been introduced 5’ to the wild-
type site on the repair template. Upon successful homologous recombination 
(blue crossovers) the gene is repaired and simultaneously the diagnostic 
restriction site is transferred to the chromosome. Note that the target site for the 
ZFN could be removed from the template (for instance by site-directed 
mutagenesis), but that would decrease the homology between target gene and 
template and likely reduce the frequency of homologous recombination. 
 
Figure 3. Detection and estimation of gene targeting. (A, B) Schematic 
representations of targeted locus and expected restriction products. Successful 
gene correction will incorporate a diagnostic restriction site next to the 
corrected point mutation. Amplification of the chromosomal target with primers 
external to the targeting construct (arrows), followed by restriction digest 
should produce three bands if gene targeting has been successful. (C) Example 
image showing detection and quantification of gene repair. Genomic DNA 
samples were PCR-amplified, digested, transferred and hybridized as described. 
Mock corresponds to non-transduced fibroblasts, and plasmid control is the 
original plasmid containing the donor template modified by site-directed 
mutagenesis. Other controls included fibroblasts transduced with IDLV-template 
alone (MOI 1,000) or IDLV-ZFN1 alone (MOI 5,000). For gene targeting 
experiments fibroblasts were transduced with IDLVs carrying the ZFN 
monomers (at the indicated MOIs) and template (at twice the indicated MOI). 
Five days after transduction, genomic DNA was isolated and tested for the 
presence of the diagnostic restriction site for gene correction. The values 
corresponding to the percentage of corrected alleles are indicated in white. 
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